GT200900032A - Derivados de oxazolidona como moduladors pr - Google Patents

Derivados de oxazolidona como moduladors pr

Info

Publication number
GT200900032A
GT200900032A GT200900032A GT200900032A GT200900032A GT 200900032 A GT200900032 A GT 200900032A GT 200900032 A GT200900032 A GT 200900032A GT 200900032 A GT200900032 A GT 200900032A GT 200900032 A GT200900032 A GT 200900032A
Authority
GT
Guatemala
Prior art keywords
endomyromatimatomy
distribution
modulators
oxazolidone derivatives
tautommers
Prior art date
Application number
GT200900032A
Other languages
English (en)
Inventor
Thomas Joseph Commons
Andrew Fensome
Gavin David Heffernan
Casey Cameron Mccomas
Richard Page Woodworth Jr
Michael Byron Webb
Michael Anthony Marella
Edward George Melenski
Ronald Charles Bernotas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of GT200900032A publication Critical patent/GT200900032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA SOLICITUD PRESENTA COMPUESTOS DERIVADOS DE OXAZOLIDONA, SALES FARMACÉUTICAMENTE ACEPTABLES, TAUTÓMEROS, METABOLITOS O PROFÁRMACOS DE LOS MISMOS, LOS CUALES SON ÚTILES PARA TRATAR UNA VARIEDAD DE AFECCIONES RELACIONADAS CON HORMONAS QUE INCLUYEN CONTRACEPCIÓN TRATAR O PREVENIR MIOMAS UTERINOS, ENDOMETRIOSIS, METRORRAGIA DISFUNCIONAL, LIOMIOMATA UTERINO, SÍNDROME DE OVARIO POLIQUÍSTICO O CARCINOMAS DEPENDIENTES DE HORMONA, QUE PROPORCIONA HORMONOTERAPIA RESTITUTIVA, QUE ESTIMULA LA INGESTIÓN DE ALIMENTO O SINCRONIZACIÓN DEL ESTRO.
GT200900032A 2006-08-15 2009-02-12 Derivados de oxazolidona como moduladors pr GT200900032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83789806P 2006-08-15 2006-08-15

Publications (1)

Publication Number Publication Date
GT200900032A true GT200900032A (es) 2011-03-29

Family

ID=39082681

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900032A GT200900032A (es) 2006-08-15 2009-02-12 Derivados de oxazolidona como moduladors pr

Country Status (22)

Country Link
US (1) US7618990B2 (es)
EP (1) EP2054410A2 (es)
JP (1) JP2010500409A (es)
KR (1) KR20090039774A (es)
CN (1) CN101501031B (es)
AR (1) AR062327A1 (es)
AU (1) AU2007284599B2 (es)
BR (1) BRPI0716622A2 (es)
CA (1) CA2659208A1 (es)
CR (1) CR10617A (es)
GT (1) GT200900032A (es)
IL (1) IL196886A0 (es)
MX (1) MX2009001698A (es)
NO (1) NO20090457L (es)
NZ (1) NZ574753A (es)
PE (1) PE20070753A1 (es)
RU (1) RU2009105113A (es)
SA (1) SA07280440B1 (es)
SV (1) SV2009003168A (es)
TW (1) TW200815428A (es)
WO (1) WO2008021331A2 (es)
ZA (1) ZA200901055B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112495A1 (en) * 2007-03-09 2008-09-18 Wyeth Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
PE20081803A1 (es) * 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CN101525310B (zh) * 2009-04-21 2019-04-16 大连九信精细化工有限公司 1-苯甲酰基-3-(2-羟基-1，1-二甲基乙基)硫脲的合成方法
ES2550319T3 (es) * 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
US9120818B2 (en) * 2010-12-14 2015-09-01 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
US9902719B2 (en) 2014-07-03 2018-02-27 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493565A (en) 1966-03-14 1970-02-03 Squibb & Sons Inc 3-amino-5-(nitrofuryl)-1,2,4-oxadiazole derivatives
DE1670338A1 (de) 1966-03-14 1972-08-10 Heyden Chem Fab Verfahren zur Herstellung von antimikrobiell wirksamen Nitrofuranderivaten
NL6809997A (es) * 1967-08-04 1969-02-06
GB1224995A (en) 1968-09-20 1971-03-10 Delalande Sa New 5-propargyloxymethyl-2-substituted oxazolidinones and their process of preparation
CA1076582A (en) * 1975-10-28 1980-04-29 Charles J. Paget Antiviral thiazolinyl or thiazinyl ketobenzimidazoles
US4293558A (en) * 1975-10-28 1981-10-06 Eli Lilly And Company Antiviral thiazolinyl benzimidazoles and derivatives
US4008243A (en) * 1975-11-19 1977-02-15 Eli Lilly And Company Antiviral thiazolinyl or thiazinyl benzimidazole esters
US4268679A (en) * 1980-02-19 1981-05-19 Ppg Industries, Inc. 3-[5- or 3-Substituted-5- or 3-isoxazolyl]-1-allyl or alkyl-4-substituted-5-substituted or unsubstituted-2-imidazolidinones
US4426527A (en) * 1982-02-12 1984-01-17 Ppg Industries, Inc. 3-[5- Or 3-substituted-1,2,4-oxadiazol-3- or -5-yl]-1-substituted-4-substituted-5-substituted or unsubstituted-2-imidazolidinones
DE3227329A1 (de) 1982-07-22 1984-01-26 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von 2-n,n-disubstituierten aminothiazolen
US4756744A (en) * 1985-06-24 1988-07-12 Ppg Industries, Inc. Herbicidally active 4-aminoalkylamino-3-isoxazolyl-2-imidazolidinone derivatives
DE3723797A1 (de) 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
CA2095429A1 (en) 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
ES2245660T3 (es) 1990-11-30 2006-01-16 Otsuka Pharmaceutical Co., Ltd. Derivados de azol y su utilizacion como inhibidores de los radicales superoxidos.
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
JPH07149745A (ja) 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−アミノチアゾール誘導体
WO1995015955A1 (de) 1993-12-06 1995-06-15 Basf Aktiengesellschaft 2,4-diaminothiazole und ihre herstellung
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19649095A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue Heteroaryl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
JP3192662B2 (ja) 1996-07-31 2001-07-30 日研化学株式会社 ６―フェニルテトラヒドロ―１，３―オキサジン―２―オン誘導体及びそれを含む医薬組成物
US5819742A (en) * 1996-11-06 1998-10-13 Family Health International Vaginal device for preventing conception or the transmission of sexually transmitted diseases, or both
DE19732928C2 (de) 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
CA2302417A1 (en) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
EP1049682A1 (en) * 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
US6562844B2 (en) * 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
JP2001261652A (ja) 2000-03-21 2001-09-26 Suntory Ltd 二置換イミノヘテロサイクリック化合物
AU2001244618A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DE10034623A1 (de) 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
DE10034622A1 (de) 2000-07-17 2002-01-31 Bayer Ag Substituierte Imidazol-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
DE10034628A1 (de) 2000-07-17 2002-01-31 Bayer Ag Pyridinhaltige Oxazolidinone als Cytokin-Inhibitoren
US20020115669A1 (en) * 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
GB0118407D0 (en) 2001-07-27 2001-09-19 Cipla Ltd Oxazolidinone derivatives as antibacterial agents
KR100437972B1 (ko) * 2001-10-27 2004-07-02 한국과학기술연구원 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
PL375532A1 (en) 2002-08-08 2005-11-28 Smithkline Beecham Corporation Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
TWI324596B (en) * 2002-08-26 2010-05-11 Nat Health Research Institutes Imidazolamino compounds
AU2003258433A1 (en) 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20040167192A1 (en) * 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
WO2004087698A2 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
CN100387594C (zh) 2003-04-03 2008-05-14 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂
US7514567B2 (en) 2003-07-08 2009-04-07 Astrazeneca Ab Oxazolidinone nicotinic acetylcholine receptor agonists

Also Published As

Publication number Publication date
NO20090457L (no) 2009-04-27
BRPI0716622A2 (pt) 2013-10-08
NZ574753A (en) 2011-04-29
US20080045556A1 (en) 2008-02-21
SV2009003168A (es) 2010-01-14
CA2659208A1 (en) 2008-02-21
KR20090039774A (ko) 2009-04-22
SA07280440B1 (ar) 2010-10-20
TW200815428A (en) 2008-04-01
JP2010500409A (ja) 2010-01-07
MX2009001698A (es) 2009-02-25
AU2007284599B2 (en) 2011-07-21
CR10617A (es) 2009-03-12
PE20070753A1 (es) 2008-08-14
ZA200901055B (en) 2009-12-30
CN101501031A (zh) 2009-08-05
RU2009105113A (ru) 2010-09-27
CN101501031B (zh) 2012-02-01
IL196886A0 (en) 2009-11-18
US7618990B2 (en) 2009-11-17
WO2008021331A3 (en) 2008-05-22
EP2054410A2 (en) 2009-05-06
AU2007284599A1 (en) 2008-02-21
AR062327A1 (es) 2008-10-29
WO2008021331A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
UY32591A (es) Inhibidores ciclicos de 11beta-hidroxiesteroide deshidrogenasa 1
GT200900032A (es) Derivados de oxazolidona como moduladors pr
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
NO20074238L (no) Fiksert dosering av HER-antistoffer
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
CO6390117A2 (es) Regimen de dosificación para un agonista de los receptores de s1p
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
CY1119547T1 (el) Ενωσεις, συνθεσεις και μεθοδοι χρησιμες για κινητοποιηση χοληστερολης
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2012003162A1 (es) Formulacion farmaceutica de administracion oral que comprende un compuesto derivado de 1-(beta-d-glucopiranosil)-3-(2-tienilmetil)benceno sustituido, un diluyente , un desintegrante, un aglutinante y un lubricante; composición farmaceutica; y metodo para tratar un trastorno mediado por transportadores de glucosa dependientes de sodio.
ECSP12011585A (es) Compuestos y composiciones para eltratamiento de enfermedades parasitarias
CR20110210A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
CL2010000804A1 (es) Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer.
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
BR112016001948A2 (pt) antagonistas de v1a para tratar distúrbios do sono de desvio de fase
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina